EL7.AI
StocksMediumUpdated•Originally published 5 October 2026•Updated 5 October 2026•
1 min read

FDA Expands Approval for Eli Lilly’s Jaypirca in First-Line Leukemia Treatment

Key Facts

1The FDA approved the expanded use of Eli Lilly's Jaypirca for adults with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

The U.S. Food and Drug Administration approved the expanded use of Eli Lilly’s drug Jaypirca for adults with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Benzinga reported that the approval specifically covers first-line treatment settings for patients without 17p deletion, supported by efficacy data from the Phase 3 BRUIN CLL-313 clinical trial.

This regulatory milestone follows a period where LLY closed at $1,142.85 on October 2, 2026. During that session, the stock reached a high of $1,164.92 and a low of $1,136.66, as the company continues to expand its addressable market within the oncology sector.

Latest Updates · 1

  1. Notable·

    Update: The U.S. Food and Drug Administration granted orphan drug designation to Eli Lilly's experimental treatment olomorasib for pancreatic cancer on October 5, 2026. This designation supports the development of therapies for rare diseases, further expanding the company's oncology pipeline following its recent approvals in leukemia treatment.

Open on chart